Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NAAA | Q02083 | 2/20 | 0.61 |
| ▸ | CTSD | P07339 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9647801 | 0.99 | NAAA (0.63) | HTTTSHRNAAACTSDHPGD | |
| SCHEMBL9172165 | 0.99 | NAAA (0.63) | HTTTSHRNAAACTSDHPGD | |
| SCHEMBL4960015 | 0.96 | HTT (0.69) | HTTTSHRNAAACTSDHPGD | |
| SCHEMBL9492867 | 0.91 | CTSD (0.66) | HTTCTSDHPGDKMT2AMEN1 | |
| SCHEMBL13753116 | 0.90 | CTSD (0.64) | HTTTSHRCTSDHPGDKMT2A | |
| SCHEMBL27530392 | 0.88 | NAAA (0.60) | HTTTSHRNAAAHPGDKMT2A | |
| SCHEMBL10974915 | 0.87 | CTSD (0.60) | HTTCTSDHPGDKMT2AMEN1 | |
| SCHEMBL9227085 | 0.84 | CTSD (0.60) | HTTCTSDHPGDKMT2AMEN1 | |
| SCHEMBL7968179 | 0.84 | CTSD (0.60) | HTTCTSDHPGDKMT2AMEN1 | |
| SCHEMBL13753006 | 0.83 | CTSD (0.68) | HTTCTSDHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| US-5914350-A | TREATING PARKINSON*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | claimed |
| US-5907061-A | AMIDATION A NITROBENZOYLHALIDE WITH A SATURATED ALKYLAMINE TO FORM A DRUG TREATING PARKINSON'S DISEASE OR SLOW THE PROGRESSIVE LOSS OF FUNCTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-05-25 | — | — | US | claimed |
| EP-0819113-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | claimed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | claimed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | disclosed |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2006-05-11 | — | — | US | disclosed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | disclosed |
| CN-1182416-A | Benzamides for neurodegenerative disorder treatment | CENTAUR PHARMACUETICALS INC (US) | 1998-05-20 | — | — | CN | disclosed |
| WO-1997038684-A1 | BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658953-A | Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5643965-A | TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | HTT 13/4885TSHR 4398/4885NAAA 46/4885 |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | HTT 13/4885TSHR 4398/4885NAAA 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.